Perioperative Iron for Colorectal Cancer (PICoC Study)

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

January 26, 2024

Study Completion Date

July 14, 2025

Conditions
Cancer Colon
Interventions
DRUG

oral ferric maltol

The intervention group will commence a course of oral ferric maltol provided oral intake has recommenced and the control group will receive standard care. All patients will have blood tests checked again at day 3 and day 5 postoperatively if they remain as an inpatient. If they are found to be anaemic on either of these two blood tests they will, at this stage, enter their allocated treatment pathway. If a patient shows no evidence of anaemia on either day 2, 3 or 5 blood tests they will be withdrawn from the study. Patients will continue treatment according to their randomisation allocation until 12 weeks after the operation, at which point the patient attends a routine surgical outpatient follow-up clinic. During the outpatient visit the participants will undergo their final blood testing and questionnaire completion.

Trial Locations (1)

Unknown

The Royal Wolverhampton NHS Trust, Wolverhampton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Norgine

INDUSTRY

lead

The Royal Wolverhampton Hospitals NHS Trust

OTHER_GOV